Business Wire

Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA

Share

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has granted inaxaplin (VX-147) Breakthrough Therapy Designation for APOL1-mediated focal segmental glomerulosclerosis (FSGS) and the European Medicines Agency (EMA) has granted inaxaplin Priority Medicines (PRIME) designation for APOL1-mediated chronic kidney disease (AMKD). Inaxaplin is the first investigational therapy aimed at treating the underlying cause of AMKD.

The FDA's Breakthrough Therapy Designation is intended to expedite development and review of medicines that aim to address a serious condition with preliminary clinical evidence indicating that the drug may demonstrate substantial improvement over existing treatments on one or more clinically significant endpoints. The Breakthrough Therapy Designation was granted based on the Phase 2 clinical study of inaxaplin in patients with APOL1-mediated FSGS, a form of AMKD.

The EMA’s PRIME designation is a regulatory mechanism that provides early and proactive support to developers of promising medicines, to optimize the generation of robust data and enable accelerated assessment so these medicines can potentially reach patients faster. The goal of PRIME is to help patients benefit as early as possible from innovative new therapies that have the potential to significantly address an unmet medical need. PRIME designation was granted based on clinical proof-of-concept data from Vertex’s Phase 2 study of inaxaplin in APOL1-mediated FSGS. Inaxaplin is only the second nephrology product to be granted PRIME designation.

Vertex now holds three of the approximately 70 non-oncological PRIME designations granted to date, including its two PRIME designations for exagamglogene autotemcel (exa-cel), formerly known as CTX001, one for transfusion-dependent beta thalassemia and one for sickle cell disease. In the US, this is the ninth breakthrough therapy designation granted to Vertex across its portfolio programs.

About the Inaxaplin (VX-147) Pivotal Program
A randomized, double-blind, placebo-controlled Phase 2/3 adaptive study is ongoing and will first evaluate two doses of inaxaplin for 12 weeks to select a dose for Phase 3 and subsequently evaluate the efficacy and safety of the single, selected dose in the Phase 3 portion of the study.

Patients aged 18 to 60 years, with two APOL1 mutations, urine protein to creatinine ratio (UPCR) ≥0.7 g/g to <10 g/g, estimated glomerular filtration rate (eGFR) ≥25 to <75 mL/min/1.73m2 and on stable doses of standard of care medications are eligible to enroll. Approximately 66 patients are planned to be enrolled in the Phase 2 dose-ranging portion of the study, and approximately 400 additional patients are planned to be enrolled in the Phase 3 portion of the study.

The primary efficacy endpoint for the final analysis is eGFR slope in patients receiving the inaxaplin selected dose compared to placebo. The secondary efficacy endpoint is time to composite clinical outcome, which will also be assessed at the final analysis and is defined as a sustained decline of ≥30% from baseline in eGFR, the onset of end-stage kidney disease (i.e., maintenance dialysis for ≥28 days, kidney transplantation, or a sustained eGFR of <15 mL/min/1.73 m2), or death. The final study analysis will occur when subjects have at least two years of eGFR data and when approximately 187 composite clinical outcomes have occurred.

The study is also designed to have a pre-planned interim analysis at Week 48 evaluating eGFR slope, supported by a percent change from baseline in UPCR in the inaxaplin arm versus placebo. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of inaxaplin in the U.S. for patients with AMKD.

About APOL1-Mediated Kidney Disease
APOL1-mediated kidney disease is a form of chronic kidney disease caused by mutations in the APOL1 gene. Approximately 100,000 people in the U.S. and Europe have two APOL1 genetic mutations and proteinuric kidney disease. People who inherit two mutations in the APOL1 gene have a course of disease that is far more aggressive than in the absence of APOL1 genetic mutations. Inherited APOL1 genetic mutations cause kidney disease through a toxic gain of function, which leads to podocyte injury. This injury disrupts filtration, resulting in proteinuria and rapidly progressive kidney disease. Progressive kidney disease can result in dialysis, kidney transplant or death.

About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 12 consecutive years on Science magazine's Top Employers list and one of the 2021 Seramount (formerly Working Mother Media) 100 Best Companies. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the expedited development of inaxaplin resulting from the FDA’s Breakthrough Therapy Designation and the EMA’s PRIME designation, the potential benefits of inaxaplin, the anticipated timelines and dosing associated with ongoing and future clinical trials, study design, including expectations on patient enrollment, expectations regarding efficacy endpoints, and plans for interim evaluation, and plans for submission for regulatory approval in the U.S. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that the trial may not be completed in the expected timeframe, or at all, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy, or other reasons, and other risks listed under the heading “Risk Factors” in Vertex's most recent annual report filed with the Securities and Exchange Commission (SEC) and available through the company's website at www.vrtx.com and on the SEC’s website at www.sec.gov. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Vertex Pharmaceuticals Incorporated
Investors:
Michael Partridge, +1 617-341-6108
or
Miroslava Minkova, +1 617-341-6135

Media:
mediainfo@vrtx.com
or
U.S.: +1 617-341-6992
or
Heather Nichols: +1 617-839-3607
or
International: +44 20 3204 5275

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Quorum Software Announces Next Generation Planning and Economics Partnership with Schlumberger30.6.2022 09:00:00 CEST | Press release

Quorum Software (Quorum), a global software leader dedicated to the energy industry, announced today that it has entered into an agreement with Schlumberger to jointly integrate Quorum’s industry-leading Planning Space, a business planning and petroleum economics offering, with the FDPlan field development planning solution, which is enabled by the DELFI cognitive E&P environment. The integrated solution will be offered directly by Schlumberger with Planning Space as its petroleum economics engine. As part of the agreement, Quorum will also acquire Merak planning, risk, and reserves software from Schlumberger. “Quorum and Schlumberger have developed longstanding relationships with our customers and partners over decades of serving the energy industry,” said Gene Austin, Chief Executive Officer at Quorum. “Bringing together our market-leading planning and economics solutions gives customers around the world access to the industry’s most complete technology ecosystem, backed by our team

ADVA unveils market’s first high-performance optical cesium clock30.6.2022 09:00:00 CEST | Press release

ADVA (FSE: ADV) today achieved an industry first with the introduction of its Oscilloquartz high-performance optical cesium atomic clock. The coreSync™ OSA 3300-HP is ADVA’s latest innovation in assured PNT, ushering in a new age of precise synchronization with unprecedented stability. Following ADVA’s launch of the first optical pumping timing solution two years ago, the OSA 3350 ePRC+, the OSA 3300-HP takes the technology to new levels. It has a 10-year lifetime compared to the five years offered by currently available high-performance magnetic clocks. As the market’s only high-performance optical cesium clock, the OSA 3300-HP sets a new benchmark for precision and availability, providing the resilience required for PNT assurance in critical infrastructure and empowering service providers to deliver differentiated SLA timing offerings with integrated GNSS backup. The feature-rich device has embedded Ethernet- and IP-based management as well as a user-friendly touchscreen GUI. This pr

Europ Assistance Group Chooses Akur8 to Strengthen Its Pricing Process30.6.2022 09:00:00 CEST | Press release

Europ Assistance Group and Akur8 are delighted to announce their collaboration to strengthen Europ Assistance's pricing process for its Travel Insurance and Car Assistance programs. By joining forces with one of the world's leading assistance companies, Akur8 is extending its European footprint and developing its expertise in the pricing of various insurance products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220610005219/en/ Specifically developed for insurers, Akur8’s solution enhances their pricing processes by automating risk modeling using Transparent Artificial Intelligence proprietary technology. Core benefits for insurers include increased predictive performance and speed-to-accuracy for higher market reactivity and immediate business impact, all while maintaining full transparency and control of the models created. In 1963, Europ Assistance invented the concept of assistance. With 24/7 assistance and an interna

Another Award for the Sturdza Family Fund30.6.2022 09:00:00 CEST | Press release

Having reached its third anniversary in December 2021 the Sturdza Family Fund and the investment team became eligible for consideration by a number of the industry’s independent rating agencies. To date, the Fund has received 4-star and 5-star Morningstar ratings (depending on the share class); a 5-Globe ‘High’ Morningstar Sustainability Rating (putting the Fund in the top 10% of all Funds within its peer group) and three of the investment team have been rated by Citywire. These all speak to the quality of the management of the Fund, particularly from a risk-adjusted perspective. We are pleased to advise therefore the Fund has received further recognition, from FundsPeople. They have classified the Sturdza Family Fund as one of their "Distinguished Investment Products of the Year" within their 2022 Fund ratings in Italy and Spain. The Sturdza Family Fund has been recognised for the consistency of the returns, with reference tovolatility versus its Morningstar-defined peer group. Additi

“Functional Art” by Braun and Virgil Abloh - Co-Created for the Brand’s 100 Years in 2021 - Features in the First Museum Exhibition Devoted to Abloh’s Work30.6.2022 08:00:00 CEST | Press release

Braun, the design-centric German appliances brand, announces its sponsorship of the Brooklyn Museum’s presentation of Virgil Abloh: “Figures of Speech” that opens to the public on July 1st, 2022, and closes January 29, 2023. The exhibition, originally organized by the Museum of Contemporary Art Chicago, spans two decades of the artist’s multifaced career, including collaborations with artists such Takashi Murakami, Juergen Teller, and Arthur Jafa; material from his fashion label Off-White and items from Louis Vuitton, where he served as the first Black menswear artistic director; and unique pieces from brand collaborations including Braun. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005028/en/ (Photo: Business Wire) To celebrate 100 years of ‘good design’ in 2021, Braun entered a one-of-a-kind collaboration with Abloh that saw him delve into the Braun archives to update and co-curate the 1965 ‘Wandanlage’ hi fi audi